Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • davids
    Junior Member
    • Jun 2016
    • 1

    #1

    d reverse complement sequences

    Hi, I am new to RNAseq and not a bioinformatician so please take my apologies if these are basic questions. After mRNA Illumina PE sequencing of 6 brain tissue samples (3 test, 3 controls), de novo assembly with Trinity (no reference genome) and DEG with bowtie2 we got: 1. a high number of very similar contigs (putative isoforms). Strangely, in each cluster of isoforms some contigs would be significantly differentially expressed in one direction while other contigs would be significantly differentially expressed in the opposite direction. I don't understand how this is possible. Having more than 90% similarity, often >99%, and assuming reads that map perfectly multiple times are distributed randomly, shouldn't read counts between very similar contigs also be similar? The end result is that at the pathway analysis step we end up with DEG showing, simultaneously, up and down regulation (as a consequence of opposite counts for isoforms that have the same functional annotation). 2. a significant number of reverse complement sequences. In this case the counts are similar and point in the same direction. However, I don't understand how these reverse complement sequences end up in the unigene list

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
35 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Working...